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ABSTRACT 
Hypoxia inducible transcription factors 
(HIFs) directly dictate the expression of 
multiple RNA species including novel and as 
yet uncharacterized long non-coding 
transcripts with unknown function. We used 
pan-genomic HIF-binding and transcriptomic 
data to identify a novel long non-coding RNA 
NICI (Non-coding Intergenic Co-Induced 
transcript) on chromosome 12p13.31 which is 
regulated by hypoxia via HIF-1 promoter-
binding in multiple cell types. CRISPR/Cas9-
mediated deletion of the hypoxia-response 
element revealed co-regulation of NICI and the 
neighboring protein-coding gene, solute carrier 
family 2 member 3 (SLC2A3) which encodes 
the high-affinity glucose transporter 3 
(GLUT3). Knock-down or knock-out of NICI 
attenuated hypoxic induction of SLC2A3 
indicating a direct regulatory role of NICI in 
SLC2A3 expression, which was further 
evidenced by CRISPR/Cas9-VPR mediated 
activation of NICI expression. We also 
demonstrate that regulation of SLC2A3 is 
mediated through transcriptional activation 
rather than post-transcriptional mechanisms 
since knock-out of NICI leads to reduced 
recruitment of RNA polymerase 2 to the 
SLC2A3 promoter. Consistent with this we 
observe NICI-dependent regulation of glucose 
consumption and cell proliferation. 
Furthermore, NICI expression is regulated by 
the VHL tumour suppressor and is highly 
expressed in clear cell renal cancer, where 
SLC2A3 expression is associated with patient 
prognosis, implying an important role for the 
HIF/NICI/SLC2A3 axis in this malignancy.  
 
INTRODUCTION 
Hypoxia is a critical feature of many 
physiological and pathophysiological 
conditions (1). Hypoxia-inducible transcription 
factors (HIFs) are a major component of the 
transcriptional response to oxygen deprivation 
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(2). Upon hypoxic exposure HIF-α subunits 
(HIF-1α and HIF-2α) are stabilized in the cell, 
following which they dimerize with HIF-1β 
and translocate into the nucleus to stimulate 
transcription of genes relevant for multiple 
regulatory pathways involved in cellular and 
organismal adaption to the hypoxic insult (e.g. 
metabolism, cell cycle, red blood cell 
production, and angiogenesis) (3,4). The HIF 
pathway can be activated in all tissues and is 
currently exploited pharmacologically in 
patients with chronic kidney disease to 
increase erythropoietin production (5). Beside 
their physiological functions, HIFs are also 
important modulators of several human 
diseases and associated pathological processes, 
including tumorigenesis (6). The direct 
relevance of HIFs for cancer progression has 
been most clearly demonstrated in clear cell 
renal cell carcinoma (ccRCC), which in most 
cases is caused by loss of the von Hippel-
Lindau (VHL) tumor suppressor (7-10). VHL-
dependent ubiquitination is necessary for 
proteasomal degradation of the HIF-α subunits 
in normoxic conditions. Therefore, 
dysfunctional VHL leads to stabilization of 
HIFs irrespective of oxygen availability 
thereby contributing to the development and 
progression of renal cancer (11).  
HIFs can activate the expression of a multitude 
of metabolic enzymes and transporters to 
optimize energy production in hypoxia (1,12). 
Together, this HIF-mediated transcriptional re-
programming of metabolism supports a shift 
towards anaerobic energy production. For 
example, increased glycolysis during hypoxia 
is supported by HIF-mediated induction of 
glucose transporters, including solute carrier 
family 2 member 1 (SLC2A1, coding for 
glucose transporter 1 (GLUT1)) and SLC2A3 
(coding for GLUT3) (13,14). Though, the 
overall increase in expression of SLC2A1 and 
SLC2A3 by hypoxia and HIF is well 
documented, detailed mechanisms of 
transcriptional regulation of these transporter 
genes by HIF are less well defined (13-17). 
The repertoire of protein-coding genes 
activated by HIF has been studied extensively 
by transcriptome analyses in a variety of 
cellular settings and, beside a small number of 
ubiquitous HIF targets (including SLC2A3), 
displays marked cell type specificity (15). 
Recent work suggests that HIFs also dictate the 
expression of several classes of non-protein 
coding genes, such as micro-RNA and long 
non-coding RNAs (18). For example, the 
micro RNA mir210 has been identified as a 
direct target of HIF, and its expression is 
associated with poor or favorable prognosis, 
respectively, depending on the type of cancer 
examined (19,20). The long non-coding RNAs, 
NEAT1 and MALAT1, are also subject to 
hypoxic regulation and have important roles in 
tumor biology (21). These findings are in line 
with recent pan-genomic analyses of 
transcriptional dysregulation in a variety of 
diseases which have highlighted the 
importance of long non-coding transcripts in 
disease progression (22). However, the 
potential breadth of long non-coding RNA 
regulation in hypoxia, and the role of such 
targets in the hypoxic response, is not yet fully 
understood. 
In recent work, we characterized global HIF-
DNA interactions and transcriptional changes 
mediated via hypoxia in MCF-7 breast cancer 
cells (4,18). We observed transcriptional 
activation of all classes of RNAs by HIF and 
identified multiple novel and previously non-
annotated RNAs with low protein-coding 
potential. These RNAs were barely detectable 
in cells exposed to ambient atmospheric 
oxygen conditions, but were highly 
upregulated in hypoxia through HIF. Here we 
investigate the function and regulation of a 
novel hypoxia-specific long non-coding RNA 
(NICI) that is directly targeted by HIF. 
Importantly, we demonstrate that NICI is co-
regulated with a neighboring gene, SLC2A3. 
Our analysis revealed a complex and non-
canonical regulation of SLC2A3 expression 
which is critically dependent on the presence 
of NICI.  
RESULTS 
HIF controls expression of a 
promoter-associated long non-coding RNA 
on chromosome 12p13.31 
To gain insights into the regulation of novel 
transcripts, we intersected existing HIF DNA-
binding data in MCF-7 breast cancer cells (400 
HIF-1 and 425 HIF-2 binding sites) with 37 
loci expressing novel RNAs regulated by 
hypoxia (4,18). We have shown earlier that all 
of these transcripts have low protein coding 
potential (18). Most of the RNAs (n=35) were 
induced by hypoxia and were at the limit of 
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detection under normoxic conditions. Of the 37 
regions expressing novel non-annotated RNAs, 
10 were adjacent to HIF-binding events (HIF-1 
and HIF-2) within ±10kb the putative 
transcriptional start site (Suppl. Table 1). 
These results suggest that HIF-binding directly 
activates transcription of a substantial part of 
the novel, hypoxia-regulated, non-annotated 
transcripts in MCF-7 cells.  
One novel transcript with HIF ChIP-seq 
signals close to the coding region is located on 
chromosome 12p13.31 (Figure 1a and 1b) 
(18). We used RNApol2 ChIP-seq in MCF-7 
cells cultured under normoxic or hypoxic 
conditions to assay for transcriptional activity 
at this locus. The presence of RNApol2 
increased in hypoxia suggesting that elevated 
levels of the transcript result from de novo 
transcription (Figure 1b). To test for HIF-
dependent transcription we interrogated 
available RNA-seq data sets from MCF-7 cells 
cultured in hypoxia with suppressed HIF levels 
(Figure 1c) (18). Though suppression of HIF-
2α had some effect on the hypoxic induction of 
the transcript, suppression of HIF-1α resulted 
in a more pronounced reduction of hypoxic 
expression indicating that the transcript is 
predominantly regulated by HIF-1. We also 
screened existing databases of long non-coding 
RNAs derived from cancer transcriptomes and 
discovered that three cancer-associated 
transcripts (CAT) overlap this region 
(CAT1466.1, CAT1466.2 and CAT1466.3) 
(22). From our RNA-seq data we infer that 
CAT1466.1 is identical to the transcript which 
is regulated by HIF (Figure 1d). We further 
analyzed epigenetic features at the HIF-
binding site and detected high levels of the 
promoter-associated histone mark H3K4me3 
and low levels of the enhancer histone mark 
H3K4me1 in MCF-7 cells (Suppl. Figure 1). 
Moreover, the levels of H3K4me3 and the 
activity mark H3K27ac increased upon 
hypoxic exposure indicating that CAT1466.1 is 
induced from a genuine promoter, rather than 
expressed as an enhancer-RNA (eRNA) 
(Suppl. Figure 1). This finding is in line with 
data from genome-wide analyses defining 
promotor- and enhancer-linked genomic 
regions which revealed strong evidence for 
promotor-associated features at this site 
(23,24). 
The long non-coding RNA NICI is co-
expressed with SLC2A3 
To date the function of long non-coding RNAs 
remains poorly understood. However, a 
number of long non-coding RNAs have a role 
in the cis-regulation of neighboring coding 
genes (25). We therefore determined the extent 
of regulation of CAT1466.1 in comparison to 
SLC2A3 which is the closest annotated gene 
approximately 35kb downstream of 
CAT1466.1. We exposed a broad selection of 
different human cell lines to the HIF-stabilizer 
dimethyloxalylglycine (DMOG) or 1% 
Hypoxia for 16h and measured expression of 
SLC2A3 and CAT1466.1 by qPCR (Figure 2a 
and suppl. Figure 2). We detected significant 
and in general comparable levels of induction 
of SLC2A3 and CAT1466.1 by DMOG or 
hypoxia, respectively. Increased expression for 
both genes was observed in most cells 
examined except for 786-O VHL re-expressing 
cells, which lack functional HIF-1α (26,27). 
Given the striking co-regulation, we suggest 
the name Non-coding Intergenic Co-Induced 
transcript (NICI) for the long non-coding RNA 
CAT1466.1. Consistent with an important role 
of HIF-1α, HIF knock-down experiments 
confirmed HIF-1α as the main inducer of both 
NICI and SLC2A3 in a sub-set of tested cell 
lines (Suppl. Figure 3). To verify the 
association of NICI and SLC2A3 expression 
with HIF-binding across cell-types, we 
inspected available HIF ChIP-seq and RNA-
seq data from additional cell lines (primary 
renal tubular cells (PTC), RCC4, HKC-8, 
T47D) for signals in this region. These 
analyses confirmed a single HIF-binding site in 
the broader genomic region of SLC2A3 which 
corresponded to the NICI promoter and 
regulation of both genes by hypoxia (Figure 
2b and Suppl. Figure 4). We also examined 
for regulation of additional neighboring 
mRNA transcripts (within 1Mb of the novel 
locus) by hypoxia in available RNA-seq data 
sets, but did not detect hypoxic regulation of 
any other gene in this region (data not shown). 
We proceeded to analyze this co-regulation in 
more detail: Expression levels of NICI and 
SLC2A3 were highly induced in primary renal 
tubular cell cultures (n=16) treated with 
DMOG (Figure 2c). Furthermore, NICI RNA 
levels correlated well with those of SLC2A3, 
consistent with a shared mode of 
transcriptional activation (Figure 2d). In this 
respect we considered the existence of a 
common RNA from which both transcripts 
arise, e.g. through alternative promoter usage. 
However, we could not detect the presence of 
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RNApol2 or any transcript in the intergenic 
region between SLC2A3 and NICI (Figure 2b, 
Suppl. Figure 4 and data not shown). We were 
also unable to detect spliced RNA products 
which cover both transcripts by PCR (data not 
shown). In addition, in time course 
experiments we measured a delayed hypoxic 
induction of SLC2A3 mRNA compared to 
NICI RNA (Figure 2e). This indicates that 
NICI and SLC2A3 expression is regulated 
from autonomous promoters. Our data suggest 
that hypoxic regulation of NICI and SLC2A3 is 
mediated via HIF-binding to a single 
regulatory element which is conserved across 
the cell lines tested. 
Regulation of NICI in renal cancer  
Following-up on the evidence for co-regulation 
of NICI and SLC2A3 by HIF, we also 
examined regulation of these genes in clear 
cell renal cell carcinoma cells (ccRCC), in 
which HIF target genes are commonly 
upregulated. We measured expression levels of 
both genes in VHL-deficient (high levels of 
HIF) and VHL-re-expressing (low levels of 
HIF) renal cancer cell lines (RCC4 and 
RCC10) exposed to control or DMOG 
conditions (Figure 3a). Here, we determined a 
significant reduction of both SLC2A3 and 
NICI RNA levels in cells re-expressing VHL 
compared to VHL-deficient cells. The 
expression of both genes was restored in VHL 
re-expressing cells following HIF-stabilization 
by DMOG, thus confirming the regulatory role 
of the VHL/HIF-axis in NICI and SLC2A3 
expression.  
Next, we proceeded to determine the RNA 
levels of NICI and SLC2A3 in 161 renal tumor 
and corresponding normal kidney samples 
collected from RCC patients from the Erlangen 
RCC cohort (126 ccRCC and 35 non-ccRCC 
patients including papillary and chromophobe 
RCCs) (28). NICI and SLC2A3 RNA were 
significantly upregulated in tumor samples 
from ccRCC patients, but not in non-clear cell 
tumors, supporting the strong association with 
the HIF pathway (Figure 3b). These results 
were also observed in data from the TCGA 
data-base: Expression levels of SLC2A3 and 
NICI (CAT1466.1) were highest in ccRCC 
samples when compared to levels from other 
tumor entities available in the database (Suppl. 
Figure 5). Interestingly, in the TCGA KIRC 
cohort high SLC2A3 mRNA expression was 
associated with an adverse prognosis (Figure 
3c). Taken together, our data from renal tumor 
cells and patients as well as data from the 
TCGA database underline the link between 
NICI/SLC2A3 regulation and the VHL/HIF 
pathway. The results also point to a relevant 
role of this regulation for the outcome of renal 
cancer patients. 
A single HIF-binding site regulates NICI 
and SLC2A3 expression 
To gain more detailed insights into how 
binding of HIF to a single site on chromosome 
12 activates the transcription of two genes we 
performed CRISPR/Cas9 mediated 
manipulation of the HIF-binding sequence. We 
conducted this in Hela cells which showed 
consistent induction of both genes by HIF-1 
(compare Figure 2a and suppl. Figure 3c). 
The core sequence of the HIF-binding site in 
the NICI promoter (hg19 chr12:8,123,206-
8,123,563 as defined by HIF-ChIP-seq in 
MCF-7) contains three hypoxia-response 
elements (HRE) (suppl. Figure 6a) (4). We 
targeted the two HREs in the center of this 
region in CRISPR/Cas9 experiments (Figure 
4a and suppl. Figure 6a). In HIF-ChIP assays 
in Hela cells, mutation of these core HREs 
significantly reduced HIF-binding compared to 
control clones of cells or wild type Hela cells 
(Figure 4b and data not shown). Importantly, 
these effects were specific since HIF-binding 
to the EGLN3 intronic enhancer at 
chromosome 14 was not affected by mutations 
at the NICI HRE indicating a preserved HIF 
response at another locus in the mutated cells 
(Figure 4b). To examine transcriptional 
consequences of reduced HIF-binding to the 
NICI HRE, we determined expression levels of 
NICI and SLC2A3 in HRE-defective and non-
defective cells upon DMOG exposure. 
Consistent with their co-regulation, we 
observed a reduced induction of both 
transcripts in HRE-mutated cells (Figure 4c). 
Thus, we have identified a specific HIF-
binding DNA element that is capable of 
regulating expression of two genes, the more 
proximal long non-coding RNA NICI and the 
more distal glucose transporter SLC2A3. 
HIF regulates SLC2A3 expression via 
induction of NICI 
HIF is able to regulate genes with 
transcriptional start sites that lie at distances 
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varying from a few base pairs to several 
hundred kilobases away from the binding site, 
and which are brought together through 
chromatin looping (4,29). Therefore, the single 
HIF-binding site on chr12p.13.31 could trans-
activate both NICI and SLC2A3 independently. 
Alternatively, the regulation of either NICI or 
SLC2A3 could be dependent upon regulation of 
the other. To test this, we first looked for 
physical interaction of the SLC2A3 promoter 
with the HIF-binding site at the putative NICI 
promoter. We performed chromatin capture 
assays in three different cell lines (786-O, 
RCC4 and MCF-7). We used sequences in the 
SLC2A3 promoter as anchor sites and 
examined possible interactions with any distant 
chromatin region using the Capture-C method 
(Figure 5a) (29,30). Although we determined 
interactions with a putative enhancer site 
approximately 24kb upstream of the SLC2A3 
promoter, no interaction was observed with the 
HIF-binding site, which regulates NICI and 
SLC2A3 expression. This finding suggests that 
induction of SLC2A3 expression by HIF is not 
initiated through direct interaction between the 
SLC2A3 promoter and the HIF-binding site at 
the NICI promoter (i.e. acting as a distant 
enhancer of SLC2A3), but may instead be 
mediated via the induction of NICI and 
subsequent regulation of SLC2A3 transcription.  
Long non-coding RNAs can be involved in 
transcriptional regulation of neighboring genes 
by various mechanisms, including recruitment 
of transcriptional modulators (e.g. activators or 
repressors) or direct interaction with the target 
transcript (31). Despite the lack of direct 
interaction between the HIF-binding site and 
the SLC2A3 promoter the strong association 
between HIF-binding and expression of both 
genes as well as the delayed induction of 
SLC2A3 compared to NICI (Figure 2e) 
suggest a functional role for NICI in regulating 
SLC2A3 expression. To validate this 
hypothesis, we first suppressed the expression 
of NICI using two different antisense 
oligonucleotides (ASOs) in Hela cells. We 
achieved 80% and 50% knock-down efficiency 
of NICI in hypoxia with NICI ASO1 and 
ASO2, respectively (Figure 5b). In line with 
our hypothesis, depletion of NICI resulted in a 
comparable reduction of SLC2A3 mRNA 
expression. Similar results for the effect of 
NICI knock-down on SLC2A3 mRNA and 
protein levels were obtained in PTC (Suppl. 
Figure 7). This suggests that NICI expression 
is necessary for hypoxic induction of SLC2A3. 
To show that NICI expression is sufficient to 
induce SLC2A3, we used a CRISPR/Cas9 
approach to induce transcription of NICI in a 
HIF-independent manner. We co-transfected 
the CRISPR/Cas9-VPR transcriptional 
activator with four different guide RNAs 
(gRNAs) targeting the core HIF-binding 
sequence including the sequence spanning the 
HRE within the NICI promoter into Hela cells. 
Increased expression of NICI was observed 
with three of the four guide RNAs when 
compared to control guides (Figure 5c). 
Importantly, these three gRNAs also increased 
levels of SLC2A3 mRNA, although only two 
reached statistical significance. Since these 
experiments were conducted under normoxia, 
we conclude that activation of NICI 
transcription is sufficient to induce SLC2A3 
expression.  
Knock-out of NICI affects RNApol2 
recruitment to the SLC2A3 promoter and 
cell proliferation 
To further dissect the mechanism of hypoxic 
SLC2A3 regulation and the role of NICI, we 
performed CRISPR/Cas9-mediated deletion of 
the NICI transcript in Hela cells (Figure 6a). 
To minimize effects on transcription factor 
binding at the NICI promoter, we targeted a 
region approximately 330bp downstream of 
the functional HRE and outside of any 
potential transcription factor binding sites as 
detected in ENCODE analyses (Suppl. Figure 
6c and data not shown). Nine clones harboring 
mutations in the NICI coding region that did 
not affect the core HRE or other putative 
regulatory regions were generated (Suppl. 
Figure 6c). Importantly, mutations in the gene 
body of NICI did not alter HIF-binding to the 
NICI HRE or the EGLN3 HRE (Figure 6b). 
However, mutation of NICI led to significantly 
reduced induction of both NICI and SLC2A3 
RNA by DMOG when compared to control 
clones (Figure 6c). To examine whether the 
regulation of SLC2A3 by NICI is mediated 
directly through transcriptional activation, we 
performed RNApol2 ChIP under DMOG 
treatment (Figure 6d). As expected from the 
HIF-ChIP experiments (Figure 6b), RNApol2 
was recruited to the HIF-binding site in the 
NICI promoter following DMOG treatment, 
which was unaffected by mutations in the NICI 
gene. Importantly however, recruitment of 
RNApol2 to the SLC2A3 promoter by DMOG 
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was significantly reduced in NICI-mutated 
clones, indicating a direct role of NICI in 
transcriptional activation of SLC2A3 
expression (Figure 6d). Finally, to test for 
functional consequences of HRE and NICI 
mutations in metabolic and growth responses 
we measured glucose consumption, lactate 
production and proliferation in hypoxia 
(Figure 7a-c). Interestingly, mutations in 
either the NICI HRE or the NICI gene body 
caused a remarkable reduction in glucose 
consumption, lactate production and 
proliferation in Hela cells under hypoxic 
conditions. Importantly, hypoxic induction of 
SLC2A1 (GLUT1), the other glucose 
transporter targeted by HIF, was not 
compromised by mutations in the NICI gene 
(Suppl. Figure 8). This suggests that binding 
of HIF at the NICI locus and activation of 
NICI is important for cell growth under 
hypoxia and that this effects is mediated by 
regulation of the SLC2A3 isoform of glucose 
transporters.  
Taken together, our experiments reveal the 
presence of a novel transcript we term NICI, 
which is transcriptionally activated by the HIF-
1 transcription factor. An intact NICI transcript 
is both necessary and sufficient for the hypoxic 
transcriptional activation of SLC2A3 by HIF 
and is involved in regulating glucose 
consumption and cell proliferation.  
DISCUSSION 
HIFs coordinate a complex 
transcriptional program that drives cell 
adaption to hypoxia. Regulation of established 
protein-coding genes has been investigated in 
detail in single gene analyses or genome-wide 
approaches. These studies revealed that HIFs 
mainly act in cis by occupying promoter-
proximal or promoter-distal regulatory 
elements to induce gene expression (3,32,33). 
In this respect, we have previously shown that 
HIF frequently binds to enhancers and that 
gene regulation may occur through looping of 
these distant sites to target promoters 
(28,29,34). Here we describe an alternative 
mechanism by which HIFs may regulate 
distant genes in trans through induction of a 
long non-coding RNA. Our experiments using 
ChIP- and RNA-seq, chromatin capture assays, 
coupled with genome editing and artificial 
transcriptional activators in a variety of 
primary and transformed cell models identify 
the promoter-associated long non-coding RNA 
NICI, and describe its functional role for 
hypoxic SLC2A3 regulation. 
Local control of gene transcription has been 
described as one of the main functions of long 
non-coding RNAs (31). Recent reports have 
highlighted this way of fine-tuning 
transcriptional activity with important 
relevance for human diseases. For example, in 
a recent genome-wide screen testing resistance 
to BRAF inhibitors in melanoma cells, 
CRISPR/Cas9-mediated activation of more 
than 10000 lncRNAs revealed 16 candidate 
loci conferring resistance to BRAF inhibition 
(25). Importantly, analysis of a subset of these 
lncRNA showed that activation of lncRNAs 
can lead to differential transcriptional activity 
of protein-coding genes in genomic vicinity 
(within 1Mb) of the respective lncRNA locus. 
These findings are in accordance with our 
results obtained in experiments with 
CRISPR/Cas9-VPR activated NICI expression, 
which led to increased SLC2A3 RNA levels.  
The HIF-binding site in the NICI promoter was 
identified in an earlier report using HIF ChIP-
seq in HUVEC cells (35). The authors also 
detected regulation of SLC2A3 and attributed 
enhancer-like functions to the HIF-binding site 
using 3C and reporter assays. Using Capture-C 
assays we did not detect chromatin looping of 
the SLC2A3 promoter to the HIF-binding site 
within the NICI locus in three different cell 
lines. The discrepancy between the two studies 
might be caused by the different methods 
applied, or by the different cell lines used 
having potentially diverse chromatin 
configurations in this region. We detected 
chromatin interactions of the SLC2A3 
promoter with a genomic region approximately 
24kb upstream of the SLC2A3 gene and 10kb 
downstream of NICI. This site has been 
described to interact with the NICI locus and 
may therefore mediate the effect of NICI on 
SLC2A3 (35).  
Both HIF-binding and expression of long non-
coding RNAs can vary considerably between 
cell types. Therefore, the conserved regulation 
of both SLC2A3 and NICI by HIF across many 
cell types is noteworthy. Indeed, this may have 
contributed to the detection of the transcript 
and the regulatory loop linking NICI to 
SLC2A3 expression in the current work. Of 
note, and in contrast to SLC2A1 and most 
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glycolytic genes which are regulated by HIF-1 
in many species including humans and mice, 
SLC2A3 is not regulated by loss of VHL in the 
renal epithelium of mice (Suppl. Figure 9). 
Consistent with this and in line with the poor 
conservation of the non-coding transcriptome 
the NICI locus is not conserved in mice (data 
not shown)(36). This suggests either that NICI 
expression is species specific or that it is 
expressed from a different locus and/or in a 
different form in other species. Therefore, 
NICI may contribute to fine-tuning of hypoxic 
SLC2A3 expression specifically in humans.  
We also considered the possibility of an 
alternative promoter usage for SLC2A3 
expression at this site. However, we could not 
detect spliced RNA products that cover both 
the NICI coding region and fragments of the 
SLC2A3 transcript in PCR analyses (data not 
shown). Furthermore, we could not detect 
RNApol2 binding or transcripts in the putative 
intronic region covering the 35kb from the 
NICI promoter to the SLC2A3 gene in any of 
our sequencing experiments. Confirming our 
observations, recent studies describe this locus 
as a region resembling features of a promoter-
associated long non-coding RNA (23,24). We 
conclude that NICI is a genuine long non-
coding RNA with low protein coding potential. 
 
Glucose transporters have a remarkable tissue-
specific expression pattern (37). For example, 
SLC2A3/GLUT3 is mainly detectable in the 
brain and the testis (38). Earlier studies 
together with our mRNA expression analyses 
and a meta-analysis of hypoxia-inducible 
genes suggest that expression of 
SLC2A3/GLUT3 is induced in tumor cells and 
under control of many tumor-associated 
pathways including the HIF-pathway (15,39). 
These observations would be in agreement 
with an important role of this high-affinity 
glucose transporter in securing energy supply 
and cell survival in hypoxic areas of certain 
tumors that have outgrown sufficiently 
oxygenated regions. Since fast growth is a 
feature of many aggressive tumors, increased 
expression of glucose transporters is associated 
with poor survival in many cancers (39). 
Therefore, pharmacological targeting of 
expression or function of glucose transporters 
is a promising strategy in oncology research 
(40). A recent study has highlighted this 
approach in glioblastoma patients in which 
high GLUT3 expression associates with an 
unfavorable outcome (41). Targeting cells 
which were dependent on GLUT3 by 
interfering with integrin and PAK4-YAP/TAZ 
signaling reduced GLUT3 expression and 
tumor cell viability introducing a novel 
approach to treat this aggressive tumor type 
(41).          
Further experiments will be necessary to 
uncover the detailed mode of action of NICI on 
SLC2A3 expression. The mechanism might 
involve direct recruitment of members of the 
transcriptional machinery or other transcription 
factors to the SLC2A3 promoter or the 
enhancer site interacting with the promoter. It 
is possible that NICI is involved in modulating 
the epigenetic signature at the SLC2A3 gene to 
permit increased transcription. It will also be of 
interest to examine the function of NICI in 
diseases associated with hypoxia signaling 
such as ccRCC. Furthermore, a detailed 
analysis of the non-coding transcriptome 
regulated by hypoxia in different cells and 
settings might reveal more such loci with co-
regulation of lncRNAs and protein-coding 
genes maybe in a more cell-type specific 
fashion.  
Experimental Procedures 
Cell culture 
Human primary tubular cells (PTC) were 
obtained from the healthy kidney cortical 
tissue of patients undergoing tumour 
nephrectomy. Isolation of these cells was 
approved by the local ethical committee at the 
University Erlangen-Nürnberg. HKC-8 cells 
were from L. Racusen. 786-O pVHL re-
expressing cells were a gift of W. G. Kaelin Jr. 
RCC4 cells were provided by C. H. Buys. 
RCC10 cells were from M. Wiesener. HK-2 
and HUH-7 were kindly provided by C. 
Warnecke. Human umbilical vein endothelial 
cells (HUVEC) were a gift from the 
Department of Molecular Cardiology, 
University Erlangen-Nürnberg. Hela, MCF-7, 
Hep3B, HepG2, HEK293T, T47D, and 
HT1080 cells were purchased from American 
Type Culture Collection. PTC were cultured in 
DMEM/Ham’s F-12 supplemented with 2 mM 
L-glutamine, 100 U ml
-1
 penicillin, 100 µg ml
-1
 
streptomycin, 5g ml
-1 
insulin, 5µg ml
-1
 
transferrin, 5 ng ml
-1
 selenium (Sigma), 10 ng 
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ml
-1
 tri-jodothronin, 1 mg hydrocortisone and 
100 µg ml
-1
 epidermal growth factor 
(Peprotech) (42). HKC-8 cells were grown as 
described previously (43). HT1080 cells were 
cultured in minimal essential medium 
supplemented with 10% fetal calf serum, 2 
mM L-glutamine, 100 U ml
-1
 penicillin and 
100 µg ml
-1
 streptomycin. All other cell lines 
were grown in DMEM supplemented with 
10% fetal calf serum, 2 mM L-glutamine, 100 
U ml
-1
 penicillin and 100 µg ml
-1
 streptomycin. 
Sub-confluent cell cultures were exposed to 1 
mM Dimethyloxalylglycine (DMOG; Cayman) 
16h before harvest. 
RNA isolation and quantification by qPCR 
Total RNA from cell culture was isolated using 
the peqGOLD Total RNA Kit or TriFast 
Reagent (VWR Peqlab) according to 
manufacturer’s instructions. Transcription of 
RNA to cDNA was performed using the High 
capacity cDNA reverse transcription kit 
(ThermoFisher Scientific). qPCRs were 
performed using Maxima SYBR Green/ROX 
qPCR Master Mix (ThermoFisher Scientific) 
on a StepOne Plus real-time PCR cycler 
(Applied Biosystems). Primers are listed in 
Suppl. Table 2. 
siRNA and ASO transfection 
siRNA against dHIF (drosophila HIF, control 
siRNA), HIF-1α and HIF-2α have been 
described previously (44) (Suppl. Table 2). 
siRNAs were transfected using SAINT-Red 
Reagent (Synvolux) with a final concentration 
of 40 nM. Scrambled and NEAT1 ASO 
controls (45) and NICI ASOs (Integrated DNA 
Technologies) were transfected using 
Lipofectamine3000 reagent (Invitrogen) with a 
final concentration of 100 nM. ASO Sequences 
are given in Suppl. Table 2. 
Chromatin immunoprecipitation 
Chromatin immunoprecipitation assays were 
performed using the Upstate protocol 
(Millipore) with minor modifications as 
described (46,47). Cells were cross-linked by 
adding 1% (w/v) formaldehyde. Cross-linking 
was quenched by addition of 125 mM glycine. 
Cells were scraped off and lysed in 1 ml SDS 
lysis buffer. Genomic DNA in cell lysates was 
fragmented using a Bioruptor Plus sonicator 
(Diagenode). For immunoprecitations, 6 µl of 
antibody solutions against HIF-1α (rabbit 
polyclonal, Cayman Chemicals, Cay10006421) 
and HIF-1β (rabbit polyclonal, Novus 
Biologicals, NB100-110) or 10 µl of RNApol2 
antibody (Santa Cruz, sc-899) were used. 
Rabbit serum served as negative control. 
Chromatin-antibody complexes were pulled 
down by Protein A agarose beads (Millipore). 
After reversal of cross-linking by heat, DNA 
was isolated by phenol-chloroform extraction. 
Samples were analyzed by ChIP-qPCR using 
Maxima SYBR green/ROX qPCR Master Mix 
on a StepOne Plus real-time cycler (Applied 
Biosystems). Primers are listed in Suppl. 
Table 2. 
Capture-C assay 
Experiments were performed as previously 
described (29,30). Briefly, 3C libraries were 
generated from 786-O, RCC4 and MCF-7 cells 
with DpnII and were sonicated to 200 bp. 
Indexed libraries were generated with 
NEBnext reagents (#E6000, # E7335, New 
England Biolabs). Capture enrichment was 
performed with the SeqCap EZ system 
(#06953212001, Roche/Nimblegen) following 
the manufacturer’s instructions. 1-
indexed library was incubated with 13 pmol of 
a pool of biotinylated oligos (Integrated DNA 
technologies or Sigma). A double capture 
protocol was followed with 48h and 24h 
hybridizations (30). Capture efficiency was 
determined with qPCR relative to a standard 
curve of genomic DNA prior to sequencing.  
Genome editing 
For genome editing, the GeneArt CRISPR 
Nuclease Vector with OFP Reporter Kit 
(Invitrogen) was used. The guide RNA 
(gRNA) was designed according to algorithms 
provided by the Zhang lab 
(http://crispr.mit.edu/). Cloning of 
CRISPR/Cas9 plasmids followed the 
manufacturer’s instructions. A total of 6 x104 
cells were transfected with 3 µg plasmid using 
Lipofectamine3000 (Invitrogen). Single-cell 
clones were generated by dilution. For 
mutation screens, genomic DNA of each clone 
was isolated by phenol-chloroform extraction 
and the CRISPR/Cas9 target region was 
amplified by PCR. PCR products were 
resolved in a 15% non-denaturating 
polyacrylamide gel. Primers are listed in 
Suppl. Table 2. Genomic DNA of clones with 
putative indel mutations were amplified by 
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PCR, cloned into a pGL3-Basic vector 
(Promega) and analyzed by Sanger sequencing. 
CRISPR/Cas9 mediated gene activation 
For CRISPR/Cas9 mediated activation of gene 
expression we used the SP-dCas9-VPR 
artificial activator (VP64-p65-Rta; Addgene 
#63798) in combination with a pSpgRNA 
plasmid (Addgene #47108) as a carrier for the 
specific gRNA (48). The gRNAs were 
designed according to algorithms provided by 
the Zhang lab (http://crispr.mit.edu). For 
cloning of the gRNA into the carrier vector we 
used the restriction enzyme BbsI according to 
the manufacturer’s instructions. A total of 3 
x10
4
 cells were transfected with 375 ng 
CRISPR/Cas9-VPR in combination with 125 
ng pSPgRNA-Nici guide using 
Lipofectamine3000 (Invitrogen). Total RNA 
was isolated as described 48h after 
transfection. 
Immunoblotting 
Cells were lysed in Urea/SDS or RIPA buffer 
added with 1x Complete Protease inhibitor 
(Roche) and 5 mM DTT. Proteins were 
fractionated by size in 10% (w/v) denaturating 
SDS-polyacrylamide gels and transferred onto 
polyvinylidene difluoride membranes. For 
detection, antibodies anti-HIF-1α (1:1000, 
rabbit polyclonal, Cayman Chemicals, 
Cay10006421), anti-HIF-2α (1:1000, goat 
polyclonal, R&D Systems, AF2997) , anti-
Glut3 (1:400, rabbit polyclonal, Abcam, 
ab15311) and anti-β-actin-HRP (1:60000, 
mouse monoclonal (AC-15), Sigma-Aldrich, 
A3854) and horseradish peroxidase-conjugated 
anti-rabbit (1:1000) and anti-goat (1:1000) 
secondary antibodies (Dako) were used. 
Protein signal was detected using Pierce ECL 
Plus Western Blotting substrate (ThermoFisher 
Scientific). Immunoreactive bands were 
quantified using the ImageQuant TL 8.1 
software (GE Healthcare) and normalized to 
signals for β-actin. Specificity of the antibodies 
was validated using siRNA mediated knock-
down of the respective proteins (for HIF-1α, 
HIF-2α please compare Suppl. Figure 3; 
SLC2A3 data not shown). 
Healthy kidney and tumor samples 
Healthy human kidney cortical tissue and 
tumor tissue from patients undergoing tumor 
nephrectomy was kindly provided by the 
Comprehensive Cancer Centre (CCC) at the 
Universitätsklinikum Erlangen. The use of this 
tissue was approved by the local ethical 
committee at the University of Erlangen-
Nürnberg and each patient gave informed 
consent. Tumor and normal kidney samples 
were examined by an expert pathologist. Pairs 
of normal kidney and tumor tissue from 126 
ccRCC and 35 non-ccRCC patients were used. 
Fresh frozen tissue was used to isolate total 
RNA using the peqGOLD Total RNA Kit and 
expression of genes was measured as described 
above.  
High-throughput sequencing data 
High-throughput sequencing experiments have 
been performed as described previously 
(4,26,29,49). Data are available at the GEO 
database.. 
Proliferation assay 
Cells were plated in triplicates at 4 x 10
3
 in 96 
well tissue culture plates in 100 µl medium. 
The next day cells were exposed to 1% O2 for 
48 or 96 h in a hypoxic incubator. An MTS 
assay was conducted after 0 h, 48 h or 96 h of 
hypoxic exposure according to according to the 
manufacturer’s instructions (Promega). 
Absorbance was measured in a microplate 
reader and normalized to background values 
derived from medium alone. 
Glucose consumption and lactate 
production 
Cells were plated at a density of 8 x 10
4
 in a 6 
well plate. The next day cells were incubated 
with 1mM DMOG in fresh growth media. 
After 24 h the supernatant was analyzed for 
glucose and lactate content using a ABL800 
FLEX blood gas analyzer (Radiometer). 
Values from medium alone (from the 
beginning of the experiment) were used to 
calculated percentage of glucose content in the 
samples. 
Statistical analysis 
Statistical analyses were performed using a 
one-sample, a two-sample or a paired t-test as 
applicable (GraphPad Prism Version 8.00 and 
Microsoft Excel 2016).  
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FIGURES 
 
Figure 1: HIF-1 induces expression of a long non-coding RNA on chr 12p13.31 
a) RNA-seq tracks and b) ChIP-seq tracks indicate induction of a transcript, HIF-binding (HIF-1α, 
HIF-2α and HIF-1β) and increased RNA-Polymerase 2 activity (RNApol2) in hypoxia at an intergenic 
site on chr 12p13.31 in MCF7 breast cancer cells. c) RNA-seq from HIF-siRNA treated MCF-7 cells 
cultured in hypoxia reveals a predominant HIF-1 dependency of the long non-coding RNA at this site. 
d) The region overlaps with cancer-associated transcripts (CAT) derived from mitranscriptome.org 
from which CAT1466.1 resembles the novel transcript.  
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Figure 2: SLC2A3 and NICI are co-regulated by HIF-1 
a) Relative NICI and SLC2A3 RNA expression levels (compared to untreated control) in a selection 
of human cell lines exposed to 1mM DMOG for 16 h as measured by qPCR (means ±SD from three 
independent experiments per cell line). Statistical analyses were performed using the one sample t-test 
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(* p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001). b) ChIP-seq analysis in primary renal tubular 
cells (PTC) confirms the single HIF-binding site at the CAT1466.1/NICI locus approximately 35kb 
upstream of SLC2A3. Expression of NICI and SLC2A3 is induced upon HIF-stabilization with 1mM 
DMOG in RNA-seq experiments. c) mRNA expression of NICI and SLC2A3 in a collection of 16 
PTC cultures left untreated or treated with 1mM DMOG for 16h. d) Expression levels of NICI 
correlate well with those of SLC2A3 in DMOG-treated PTC. e) Time course of relative expression 
levels of NICI and SLC2A3 RNA in PTC exposed to 1mM DMOG for the indicated time.  Data is 
normalized to time point 0h and bars represent means ±SD measured in cells from n=3 individuals. 
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Figure 3: Expression of NICI and SLC2A3 in renal cancer 
a) NICI an SLC2A3 are regulated via VHL and HIF. Expression qPCR analysis of renal cancer cell 
lines RCC4 VHL +/- and RCC10 VHL+/- treated with 1mM DMOG for 16h or left untreated. Values 
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are means ±SD from three independent experiments. b) Box-and-whisker plot of RNA expression 
levels of NICI and SLC2A3 in samples from clear cell renal cell carcinoma (ccRCC; n=126) and non-
clear cell renal cell carcinoma (non-ccRCC; n=35) from the Erlangen RCC cohort compared to 
corresponding normal renal tissue. Values were measured by qPCR and normalized to the expression 
levels of actin B (ACTB). The horizontal lines represent the average value, and the whiskers extent to 
the 10
th
 and 90
th
 percentile, respectively. Statistical analyses were performed using the two-sample t-
test (* p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001). c) Kaplan-Meier survival curve of renal 
cancer patients from the TCGA KIRC cohort stratified for high (red) or low (blue) SLC2A3 
expression. Data were derived from oncolnc.org. 
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Figure 4: HIF-binding to the NICI locus regulates SLC2A3 expression 
a) The HRE (HRE mut) targeted by a specific guideRNA and CRISPR/Cas9 mediated genome editing 
is highlighted in orange in the NICI promoter. b) HIF-binding to the NICI HRE and the control locus 
EGLN3 in NICI HRE-mutated clones (n=2) and a control clone of cells is shown by ChIP-qPCR 
(values are from three independent experiments). c) Relative RNA expression levels of untreated or 
DMOG (1mM for 16 h) stimulated Hela wild-type cells (wt) or clones with (HRE mut#1 and HRE 
mut#2) or without (HRE mut control) mutations in the HRE (n=6 independent experiments). Data 
represent means ±SEM. Statistical analyses were performed using the Student’s t-test (* p<0.05; ** 
p<0.01; **** p<0.0001). 
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Figure 5: Activation of NICI expression is necessary for SLC2A3 regulation 
a) Capture-C assay reveals chromatin interaction between the SLC2A3 promoter (anchor site, 
highlighted in light green) and an intergenic site approximately 24 kb upstream of the promoter 
(highlighted in grey) in 786-O, RCC4 and MCF-7 cells. No interactions were detected with the NICI 
promoter (highlighted in light blue). b) Knock-down of NICI in Hela cells using two different 
antisense oligonucleotides (ASO) targeting NICI (NICI 1 and NICI 2), a non-targeting scrambled 
control (scr.) and an ASO targeting the long non-coding RNA NEAT1 (n=6 independent experiments). 
Expression qPCR from DMOG treated (1mM for 16 h) and untreated cells was performed for NICI 
and SLC2A3 RNA. Values were normalized to HPRT and untreated scrambled control samples. c) 
Epigenetic modulation of the NICI promoter by the activator CRISPR/Cas9-VPR leads to increased 
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NICI and SLC2A3 expression (n=6 independent experiments). Four different guideRNAs against the 
NICI promoter, pSPsgRNA empty vector or an independent guideRNA targeting the IL1R promoter 
were used. Values were normalized to results from pSPsgRNA control samples. Statistical analyses 
were performed using the one sample t-test (* p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001). 
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Figure 6: NICI mediates hypoxic SLC2A3 indcuction 
a) The site within the NICI transcript targeted by the guide RNA for CRISPR/Cas9 mediated mutation 
is highlighted in green (NICI mut). b) HIF ChIP-qPCR for the NICI HRE and the control HRE in the 
EGLN3 intronic region. DNA fragments were captured by ChIP using HIF-1β antibodies or serum 
control in clones with mutations in the NICI transcript (NICI mut; n=4 independent clones) or control 
clones (control; n=4 independent clones). Cells were exposed to 1 mM DMOG for 16h. c) Expression 
qPCR for NICI and SLC2A3 in untreated or DMOG treated clones with (NICI mut; n=9 independent 
clones) or without mutations in the NICI transcript (control; n=5 independent clones). Results are from 
three independent experiments for each clone of cells. d) RNA Polymerase 2 (RNApol2) DNA 
interactions were determined by ChIP qPCR at the NICI HRE and the SLC2A3 transcriptional start site 
(TSS) in NICI transcript-mutated clones (n=4) compared to control clones (n=4). Cells were exposed 
to 1 mM DMOG for 16h.  
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Figure 7: NICI regulates glucose consumption and proliferation 
a) Glucose consumption and b) lactate in culture media from hypoxic cells. Cells (n=2 for HRE mut, 
n=3 for NICI mut, n=4 for mut control) were cultured in 1mM DMOG for 24h before glucose 
consumption and lactate were measured in the medium. c) MTS proliferation assay with cells from a) 
performed in triplicates per time point under hypoxic conditions (1% O2). Statistical analyses were 
performed using the one or two sample t-test (* p<0.05; ** p<0.01; **** p<0.0001) comparing values 
from NICI/HRE mutated cells to the respective values from control clones (mut control). 
 
 
 
